Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Cytarabine

If you want to know more about the Cytarabine, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Cytarabine industry. More news about Cytarabine, are being released. Follow us / contact us for more Cytarabine information!
  • Drug Patent & Exclusivity Expiration Report - Week of April 21 2025

    Drug Patent & Exclusivity Expiration Report - Week of April 21 2025

    2025-04-21

    This week, there are 18 drugs in the patent and exclusivity list. They are: - VIIV HEALTHCARE CO's JULUCA, containing active ingredient DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JANSSEN PRODUCTS LP's EDURANT, containing active ingredient RILPIVIRINE HYDROCHLORIDE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - GILEAD SCIENCES INC's COMPLERA, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - CELATOR PHARMACEUTICALS INC's VYXEOS, containing active ingredient CYTARABINE; DAUNORUBICIN - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE Read More